Ligand Pharmaceuticals (LGND) EBT Margin (2010 - 2026)
Ligand Pharmaceuticals (LGND) reported EBT Margin of 46.9% for Q1 2026, up 6379.0% on a YoY basis from 0.72% in Q1 2025, and down 149.29% sequentially from 95.16% in Q4 2025.
Ligand Pharmaceuticals (LGND) EBT Margin (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 17 years of EBT Margin data on file, last reported at 46.9% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 6379.0% year-over-year to 46.9%; the trailing twelve-month figure through Mar 2026 stood at 67.36% (up 15613.0% YoY), and the FY2025 full-year result was 59.29%, up 5779.0% from the prior year.
- EBT Margin fell to 46.9% in Q1 2026, from 95.16% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 366.22% in Q1 2024 to a low of 157.45% in Q2 2024.
- A 5-year average of 24.21% and a median of 17.28% in 2022 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin jumped 23994 bps in 2024 and tumbled 47691 bps in 2025, its largest moves.
- Tracing LGND's EBT Margin over 5 years: stood at 47.91% in 2022, then gained by 27 bps to 60.84% in 2023, then plunged by 250 bps to 91.56% in 2024, then surged by 204 bps to 95.16% in 2025, then plunged by 149 bps to 46.9% in 2026.
- Business Quant data shows LGND's EBT Margin at 46.9% in Q1 2026, 95.16% in Q4 2025, and 122.24% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | -46.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.90% |
| Dec 31, 2025 | 95.16% |
| Sep 30, 2025 | 122.24% |
| Jun 30, 2025 | 23.56% |
| Mar 31, 2025 | -110.69% |
| Dec 31, 2024 | -91.56% |
| Sep 30, 2024 | -12.23% |
| Jun 30, 2024 | -157.45% |
| Mar 31, 2024 | 366.22% |
| Dec 31, 2023 | 60.84% |
| Sep 30, 2023 | -36.95% |
| Jun 30, 2023 | 12.03% |
| Mar 31, 2023 | 126.28% |
| Dec 31, 2022 | 47.91% |
| Sep 30, 2022 | 20.86% |
| Jun 30, 2022 | 17.28% |
| Mar 31, 2022 | -25.04% |
| Dec 31, 2021 | 31.70% |
| Sep 30, 2021 | 25.56% |
| Jun 30, 2021 | 42.23% |